Lirilumab (IPH2102) is an anti-KIR monoclonal antibody, and shows antitumor activity. Lirilumab can be used in Leukemia, squamous cell carcinoma of the head and neck (SCCHN) research[1][2].
Molecular Weight:
(145.52 kDa)
Purity:
96.80
CAS Number:
[1000676-41-4]
Target:
Transmembrane Glycoprotein
Application Notes:
MCE Product type: Inhibitory Antibodies
* VAT and and shipping costs not included. Errors and price changes excepted